Source comparison
Comparison: Sermorelin vs Other Peptide Protocols for Anti-Aging
Sermorelin GHRH analog. Stimulates endogenous GH pulse from pituitary 8–12 weeks for body composition; 6+ months for skin/collagen Daily subcutaneous injection (bedtime) Prescription required; not FDA-approved for anti-aging but legally prescribed off-label Be
This comparison does not assign a generated winner or score.
- Sermorelin
- GHRH analog. Stimulates endogenous GH pulse from pituitary
- 8–12 weeks for body composition; 6+ months for skin/collagen
- Daily subcutaneous injection (bedtime)
- Prescription required; not FDA-approved for anti-aging but legally prescribed off-label
- Best for patients with intact pituitary function seeking natural GH elevation without suppressing endogenous production. Requires consistency but avoids receptor downregulation
- Ipamorelin + CJC-1295 (DAC)
- Dual agonist. Ghrelin mimetic + GHRH analog with extended half-life
- 6–10 weeks for fat loss; synergistic with resistance training
- 2–3× weekly subcutaneous
- Prescription required; research peptides sold under 'research use only' disclaimer
- More potent GH release than sermorelin alone due to dual pathway activation. Higher incidence of water retention and cortisol elevation at doses >300 mcg; best for aggressive recomposition goals
- Growth Hormone (Somatropin)
- Direct exogenous GH replacement. Bypasses pituitary entirely
- 4–6 weeks for body composition; immediate IGF-1 spike
- Daily subcutaneous
- FDA-approved for specific deficiency diagnoses only; heavily regulated
- Fastest results but suppresses natural GH production during use; requires medical supervision due to insulin resistance risk and legal/cost barriers. Not a first-line anti-aging option
- MK 677 (Ibutamoren)
- Oral ghrelin receptor agonist. Mimics hunger hormone to trigger GH release
- 8–12 weeks for lean mass increase; appetite stimulation within days
- Once daily oral capsule
- Research compound. Not FDA-approved; gray-area legal status
- Convenient oral administration but notorious for causing ravenous hunger (20–30% increase in appetite) and water retention; useful for lean mass gains but problematic for fat loss goals
- The comparison underscores a critical point: sermorelin's slower timeline isn't a weakness. It's a design feature. The peptide doesn't shut down your natural GH axis the way exogenous somatropin does, and it doesn't trigger the intense appetite surge that makes MK 677 difficult to sustain for fat loss. Our experience working with research subjects shows that protocols combining sermorelin with CJC1295 Ipamorelin 5MG 5MG produce faster body composition changes but require closer monitoring for side effects.